fbpx

Weekly Top News – IBD – January 27, 2020

January 27, 2020

JNJ-64304500 / J&J
JNJ-64304500: NME filing in US for Crohn’s disease between 2020-2023 (J&J) – Jan 22, 2020 – Pipeline Update: Regulatory submission in EU for Crohn’s disease between 2020-2023 
[Screenshot]

 

Tremfya (guselkumab) / J&J
Tremfya: Data from P2/3 GALAXI trial (NCT03466411) for Crohn’s disease in 2020 (J&J) – Jan 22, 2020 – Key 2020 Events 
[Screenshot]

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn’s Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989 (clinicaltrials.gov) – Jan 21, 2020 – P3; N=1250; Recruiting; Sponsor: AbbVie; N=912 –> 1250

 

Stelara (ustekinumab) / J&J
NICE rejects Janssen’s Stelara on cost efficiency grounds (PharmaTimes) – Jan 22, 2020 – “The National Institute for Health and Care Excellence (NICE) has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ulcerative colitis in adults….NICE said that it already recommends several treatment options…The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment, but the company has agreed a confidential pricing arrangement for the drug with the Commercial Medicines Unit.”

 

Remicade (infliximab) / Mitsubishi Tanabe, J&J
Remicade ex-US sales estimate: $400M in 2019; Remicade ex-US sales projection: $300M in 2020 and $5M in 2025 (Cowen & Co) – Jan 21, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 494; REPORT TITLE: – “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

 

PF-06480605 / Pfizer
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) – Jan 23, 2020 – P2b; N=240; Recruiting; Sponsor: Pfizer; Not yet recruiting –> Recruiting

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz sales estimate: $2.275B in 2019; Xeljanz sales projection: $2.645B in 2020 and $4.405B in 2025 (Cowen & Co) – Jan 22, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 670; REPORT TITLE: – “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi sales estimate: $275M in 2019; Skyrizi sales projection: $850M in 2020 and $3.4B in 2025 (Cowen & Co) – Jan 21, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 72; REPORT TITLE: “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

 

Humira (adalimumab) / Eisai, AbbVie
Humira sales estimate: $19.125B in 2019; Humira sales projection: $18.955B (guidance: $21B) in 2020, $14B in 2023, $10B in 2024 and $5.5B in 2025 (Cowen & Co) – Jan 21, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 35, 52; REPORT TITLE: “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

 

Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Simponi ex-US sales estimate: $835M in 2019; Simponi ex-US sales projection: $795M in 2020 and $550M in 2025 (Cowen & Co) – Jan 21, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 494; REPORT TITLE: – “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

No Comments

Post a Comment

Comment
Name
Email
Website